494 episodes
Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B
11/05/2026 | 14 mins.CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting.From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada
11/04/2026 | 19 mins.Sofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what Montreal and other Canadian biotech hubs do well, what could be improved, and the environment for entrepreneurs to turn ideas into companies.Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC
11/03/2026 | 11 mins.CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
10/29/2026 | 21 mins.President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2
10/27/2026 | 22 mins.CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.
Listen to BiotechTV - News, Health Optimization Medicine Podcast and many other podcasts from around the world with the radio.net app
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
BiotechTV - News
download the app,
start listening.
USA
